No ASH pre-conference coverage would be the same without a shout out to Dr John Leonard (Weill Cornell). For 10 days prior to the annual meeting he counts down each day with a lymphoma study that caught his attention and tags it #LeonardList. The first one went up yesterday:
Time for #ASH17 #Leonardlist Number 10 Abs 486 Salles 10-yr f/u of PRIMA study rituximab maintenance after R-chemo in frontline follicular #lymphoma pts – Survival appears good in BOTH arms & pts can avoid/decline 2 yr maint rituximab without concern/risk https://t.co/yiI6FbuNKE pic.twitter.com/K5KiwVBLXM
— John P. Leonard, MD (@JohnPLeonardMD) November 29, 2017
Do follow Dr Leonard and his lymphoma selections on Twitter – there are usually surprising ones in the middle that are quirky or interesting that makes you stop and think more carefully. He also appeared on the #ASH16 Novel Targets podcast in Season 2 explaining his choices and why they mattered if you want to get a flavour.
Up next in our third ASH17 Preview, we take a broad look at the wealth of abstracts available and highlight ten key presentations, irrespective of tumour type, which readers should be watching out for.
Some of these ‘Champions’ may not be immediately obvious and include interesting preclinical findings, intriguing new products in development, as well as eagerly awaited mature data from recently approved therapies. It’s an eclectic mix, to be sure.
There are definitely some early trends and interesting new molecules emerging from company R&D pipelines that are worthy of further consideration in this year’s batch of abstracts.